Blood:抗生素抑制皮肤T细胞淋巴瘤患者肿瘤和疾病活动

2019-07-23 xing.T MedSci原创

总之,该研究提供了新的证据表明积极的抗生素治疗可抑制皮损中的恶性T细胞。因此,该研究提供了治疗晚期CTCL患者SA的新理论基础。

已有研究推测CD4T细胞对金黄色葡萄球菌(SA)的反应可无意中增强皮肤癌和皮肤T细胞淋巴瘤(CTCL)模型中的肿瘤进展。

近日,心液病领域权威杂志Blood上发表了一篇研究文章,在这项前瞻性研究中,研究人员旨在通过8例晚期CTCL患者探究短暂抗生素治疗对肿瘤细胞和疾病活动的影响。

所有患者在接受积极的、短暂抗生素治疗后都经历了临床症状的显著降低。在一些患者中,临床改善可持续超过8个月。8名患者中的6名患者可以在损伤皮肤中鉴定出恶性T细胞克隆,并且在抗生素治疗之后观察到恶性T细胞的比例显著降低,但是其他治疗方式未改变。免疫组织化学、全mRNA表达和细胞信号通路分析表明短暂积极的抗生素治疗与损伤皮肤中IL-2高亲和力受体(CD25)表达、STAT3信号传导和细胞增殖能力降低有关。

总之,该研究提供了新的证据表明积极的抗生素治疗可抑制皮损中的恶性T细胞。因此,该研究提供了治疗晚期CTCL患者SA的新理论基础。 

原始出处:

Lise M. Lindahl.et al.Antibiotics inhibit tumor and disease activity in cutaneous T cell lymphoma.Blood.2019.http://www.bloodjournal.org/content/early/2019/07/22/blood.2018888107

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1756082, encodeId=18f01e56082a3, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Tue Feb 04 21:45:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702579, encodeId=56fb1e025797b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Sep 12 06:45:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372657, encodeId=dcda13e26572e, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584232, encodeId=174e158423270, content=<a href='/topic/show?id=9c55e1986b9' target=_blank style='color:#2F92EE;'>#皮肤T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71986, encryptionId=9c55e1986b9, topicName=皮肤T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c717034263, createdName=12498f17m71暂无昵称, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1756082, encodeId=18f01e56082a3, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Tue Feb 04 21:45:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702579, encodeId=56fb1e025797b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Sep 12 06:45:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372657, encodeId=dcda13e26572e, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584232, encodeId=174e158423270, content=<a href='/topic/show?id=9c55e1986b9' target=_blank style='color:#2F92EE;'>#皮肤T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71986, encryptionId=9c55e1986b9, topicName=皮肤T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c717034263, createdName=12498f17m71暂无昵称, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1756082, encodeId=18f01e56082a3, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Tue Feb 04 21:45:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702579, encodeId=56fb1e025797b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Sep 12 06:45:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372657, encodeId=dcda13e26572e, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584232, encodeId=174e158423270, content=<a href='/topic/show?id=9c55e1986b9' target=_blank style='color:#2F92EE;'>#皮肤T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71986, encryptionId=9c55e1986b9, topicName=皮肤T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c717034263, createdName=12498f17m71暂无昵称, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1756082, encodeId=18f01e56082a3, content=<a href='/topic/show?id=78e1e06924a' target=_blank style='color:#2F92EE;'>#疾病活动#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70692, encryptionId=78e1e06924a, topicName=疾病活动)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=57fa37069463, createdName=xue8614, createdTime=Tue Feb 04 21:45:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1702579, encodeId=56fb1e025797b, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu Sep 12 06:45:00 CST 2019, time=2019-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372657, encodeId=dcda13e26572e, content=<a href='/topic/show?id=7d2d1802820' target=_blank style='color:#2F92EE;'>#T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18028, encryptionId=7d2d1802820, topicName=T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584232, encodeId=174e158423270, content=<a href='/topic/show?id=9c55e1986b9' target=_blank style='color:#2F92EE;'>#皮肤T细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71986, encryptionId=9c55e1986b9, topicName=皮肤T细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c717034263, createdName=12498f17m71暂无昵称, createdTime=Thu Jul 25 12:45:00 CST 2019, time=2019-07-25, status=1, ipAttribution=)]

相关资讯

NEJM:C-反应蛋白监控与COPD患者抗生素用量

研究认为,C-反应蛋白监控可显著减少慢性阻塞性肺疾病急性加重期患者护不必要的抗生素使用

英国推出抗生素创新商业模式 政府先采购企业再开发

7月9日,英国卫生与社会关怀部(Department of Health and Social Care)宣布将通过新的药品支付系统鼓励新型抗生素的研发。国家医疗服务体系(National Health Service,NHS)将试验全球首个“订阅”式支付模式,以激励制药公司开发抗药性感染的新药,使英国成为世界上第一个试验全新抗生素支付方式的国家。

BMC Pediatr: 儿童中早期抗生素接触与哮喘和过敏性鼻炎发展研究

在过去的几十年中,儿科过敏性疾病的患病率增加迅速。最近的研究表明了过敏性疾病的增加与早期肠道微生物的失调相关。肠道微生物在出生时形成并且在出生后1年内很容易失调。早期的抗生素接触可能对肠道微生物的组成造成不良的影响,并造成生态失调,从而增加儿童患过敏性疾病的风险。最近,有研究人员进行了回顾性的图表分析,数据时间为2007年到2016年。入选的标准为在洛约拉大学医学中心(LUMC)出生且至少具有2次

J Dent Res:口腔医生抗生素处方的副作用风险分析

口腔医生在临床诊疗中会开具大量的抗生素处方,而这与药物的副作用风险(ADRs)存在一定的联系。这篇研究的目的是为了定量分析口腔医生常规开具的抗生素处方与ADRs之间的联系。

2019 KSID指南:抗生素在急性胃肠炎中的应用

2019年6月,韩国感染病学会(KSID)发布了抗生素在急性胃肠炎中的应用指南,急性胃肠炎是社区成年人常见的感染性疾病,该指南是对2010年成人胃肠道感染的诊治指南的更新,新版指南主要建议内容涉及,流行病学因素,诊断测试,经验性抗生素治疗的适应证以及病原菌确定后抗生素的应用。

Cell:流感吃抗生素没用!或成肺炎爆发“帮凶”

最近,伦敦弗朗西斯•克里克研究所的科学家们在《Cell Reports》杂志上发表了关于抗生素的最新研究,再次证明了抗生素的滥用不仅产生耐药性,还甚至可能成为流感病毒肆虐的“帮凶”,帮助其破坏人体免疫应答,让流感感染更加严重。